433-13-6

Upstream product

• 74-97-5 chlorobromomethane 
• 349-88-2 4-Fluorobenzenesulfonyl chloride 

Downstream Products

• 1009372-79-5 1-chloromethanesulfonyl-4-(p-tolyloxy)-benzene 
• 1146349-20-3 4-(4-fluorobenzenesulfonylmethyl)-1-methyl-5-nitro-1H-imidazole 
• 1146349-23-6 4-(4-fluorobenzenesulfonylmethyl)-1,2-dimethyl-5-nitro-1H-imidazole 
• 1146349-28-1 2-[4-(4-fluorobenzenesulfonylmethyl)-2-methyl-5-nitroimidazol-1-yl]ethanol 
• 1146349-32-7 1-[4-(4-fluorobenzenesulfonylmethyl)-2-methyl-5-nitroimidazol-1-yl]propan-2-ol 
• 1253422-18-2 C₁₈H₂₀FN₃O₄S 
• 744219-24-7 1-{5-Chloro-2-nitro-3-{[(4-fluorophenyl)sulfonyl]methyl}phenyl}-4-methylpiperazine 

Relevant academic research and scientific papers

Lowering of 5-nitroimidazole's mutagenicity: Towards optimal antiparasitic pharmacophore

To improve the antiparasitic pharmacophore, 20 5-nitroimidazoles bearing an arylsulfonylmethyl group were prepared from commercial imidazoles. The antiparasitic activity of these molecules was assessed against Trichomonas vaginalis, the in vitro cytotoxicity was evaluated on human monocytes and the mutagenicity was determined by the Salmonella mutagenicity assay. All IC50 on T. vaginalis were below the one of metronidazole. The determination of the specificity indexes (SIs), defined as the ratios of the cytotoxic activity and the antitrichomonas activity, indicated that 11 derivatives had a SI over the one of metronidazole. Molecules, bearing an additional methyl group on the 2-position, showed a lower mutagenicity than metronidazole. Moreover, three derivatives were characterized by a low mutagenicity and an efficient antitrichomonas activity.

HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS

This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.

Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs)

Several classes of arylsulfone-based MMP-2/-9 inhibitors utilizing 6- to 8-membered heterocyclic rings as zinc-binding groups (ZBGs) have been synthesized and their enzyme inhibitory activities were evaluated. Although a number of 6- and 7-membered hetero